Table 5 : Correlation of DNA-ploidy with overall survival.


Authors Year Journal Number of
patients
Months
follow-up
Significance p Flow/Image
cytometry
Comment

After RPE

Oxford level 2b

Ward et al., [198] 2005 BJU International 816 123.6 0.008 FCM cT3 only
Martinez –Jabaloyas et al., [199] 2004 Actas Urol Espan 54 120 0.009 FCM With bone marrow
metastases
Amling et al., [178] 1999 J Urol 106 120 0.001 FCM After external radiation
Myers et al., [200] 1997 J Urol 62 >120 0.0014 FCM Plus hormonal treatment
Di Silverio et al., [201] 1996 Eur Urol 85 35 0.05 FCM --
Zincke et al., [182] 1992 Cancer 370 60 0.004 FCM Plus hormonal treatment

Oxford level 3b

Bratt et al., [202] 1996 Urology 57 54-92 0.009 FCM S-phase fraction
Tinari et al., [203] 1993 Cancer 63 84 0.0044 FCM Stages T1-T4
Miller et al., [204] 1991 J Urol 103 60 <0.001 FCM Stage D2
Montgomery et al., [190] 1990 Arch Surg 261 240 <0.0001 FCM Stage B

After external radiation

Oxford level 3b

Pollack et al., [205] 2003 J Clin Oncol 149 96 0.05 ICM --
Song et al., [206] 1992 J Urol 65 >120 0.0001 ICM Cancer cause specific
survival

After brachytherapy

Oxford level 2b

Stephenson et al., [207] 1987 Cancer Res 82 60-180 0.0109 FCM D1, N1, measured on
lymphnodes

After hormonal therapy

Oxford level 2b

Martinez-Jablonayas et al., [208] 2002 Urology 127 >120 0.031 FCM --
Pollack et al., [209] 1997 Prostate 33 45 0.008 FCM --
Ahlgren et al., [210] 1997 Urology 96 176 0.004 ICM --
Forsslund et al., [211] 1996 Cancer 334 360 0.001 ICM --
Jörgensen et al., [212] 1995 Brit J Cancer 59 36 n. s. ICM Neither GS nor WHO-grade correlated
Vesalainen et al., [169] 1994 Brit J Cancer 273 156 0.058 FCM T1-2. M0
Al Abadi et al., [213] 1992 Eur Urol 271 >=24 <0.015 FCM T1-4

Oxford level 3b

Tribukait., [110] 1993 Eur Urol 309 176 <0.0001 ICM --
Van den Ouden et al., [214] 1993 J Urol 963 96 0.023 FCM Stages T1-T4
Di Silverio et al., [215] 1992 Eur Urol 80 60 <0.005 FCM Stage A-D
Forsslund et al., [216] 1992 Cancer 145 276 <0.001 ICM Cytological grade
Fordham et al., [217] 1986 Br J Surg 72 6-144 <0.001 FCM HT in 73%

Oxford level 4

Miller et al., [204] 1991 J Urol 103 >60 <0.001 FCM Stage D2

After active surveillance

Oxford level 3b

Vesalainen et al., [169] 1994 Brit J Cancer 106 156 0.02 FCM T1-2, M0
Tribukait., [110] 1993 Europ Urol 287 176 <0.001 FCM FNABs

Oxford level 4

Tribukait., [218] 1991 Acta Oncol 125 72 n.n. FCM FNABs

Oxford level 3b

After TUR

Oxford level 2b

Borre et al., [219] 1998 Prostate 120 180 0.024 FCM 96 WHO low grades only

Bold p-values refer to Cox multivariate regression analysis.

Böcking et al.Pathology Discovery  2014 2:7DOI : 10.7243/2052-7896-2-7